recent post

Our Hubs Drive Collaboration and Innovation for Startups and Enterprises: Milind Ravi- CEO, Rx Propellant

December 7, 2024
recent post

Lupin’s R&D Facility in Pune bags LEED Platinum Certification

December 6, 2024
recent post

MediBuddy launches India Health Care Collaborators to enable insurance-integrated healthcare

recent post

Dr Kanimozhi K joins ART Fertility Clinics as Director and Clinical Lead

recent post

Medanta opens MediClinic at Golf Course Road, Gurugram

4baseCare expands global footprint, launches operations in Dubai

4baseCare expands global footprint, launches operations in Dubai

The company has setup a state-of-the-art genomics lab at Dubai Science Park

4baseCare, an Illumina Accelerator Company, that offers cutting-edge precision oncology solutions using advanced genomics and digital health technology, has launched operations in Dubai by establishing a state-of-the-art genomics lab at Dubai Science Park, in collaboration with Innovate Life Sciences. 

The expansion aligns with 4baseCare’s strategic plan to strengthen its footprint across Southeast Asia and the Middle East. The recent $6 million fund raise from Yali Capital has played a pivotal role in fueling this growth and paving the way for further expansion across other international geographies. 

The launch event was held on October 17, 2024, in the esteemed presence of Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, and Iqbal Khan, CEO of Fajr Capital, as Guests of Honour. 

4baseCare’s new genomics lab will provide cutting-edge genomic testing solutions, including comprehensive cancer gene panels, whole exome sequencing, and transcriptome analysis. These advanced tools will enable oncologists to delve deeper into the genetic makeup of tumours, offering personalised and more effective treatment options. 

Iqbal Khan, CEO, Fajr Capital, expressed, “The partnership and cancer genomics services launch is more than a scientific milestone; it’s a profound step forward in the fight against cancer for individuals and families across the Middle East. This lab is a beacon of hope, symbolizing the convergence of science, innovation, and compassion. By leveraging the power of genomics, we are reimagining cancer care, creating pathways for personalised treatments tailored to each patient’s unique genetic profile. Today marks a pivotal moment—a future where every patient’s treatment is as individualized as their needs, offering not only healing but a renewed sense of hope for tomorrow.”

“Genomics is essential to unlock life-changing therapies, and 4baseCare's partnership with Innovate Life Sciences, one of more than 500 industry leaders at Dubai Science Park, is a pivotal step in harnessing its potential,” said Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, TECOM Group. “As the address of collaborations such as Innovate Life Sciences with 4baseCare, Dubai Science Park’s community is enabling healthcare advancements to benefit patients, in line with the goals of Dubai Research and Development Programme and Dubai Economic Agenda ‘D33’.” 

Hitesh Goswami, CEO, 4baseCare, said, “Cancer touches us all—our families, our friends, our communities. The global burden of this disease continues to grow, and we cannot wait any longer to act. Through this partnership, we are bringing hope to cancer patients across the Middle East. We are committed to ensuring that advanced, personalised cancer care is within reach for everyone who needs it.” 

“Our new partnership at Dubai Science Park is a collaborative effort to manage the economic burden of cancer and expand access to cancer care. The rising costs of controlling cancer are an undeniable challenge for the ME region. The long-term sustainability of oncology care will require the collaboration of various stakeholders. With this partnership, we are fully committed to helping clinicians and patients in the Middle East access the best that precision oncology has to offer,” Hitesh added. 

4baseCare also unveiled SoLiq- A solid-liquid NGS tests portfolio that combines the best of both worlds—solid and liquid biopsy technologies—to give oncologists a 360° view of tumor biology.